Tracers / [212Pb]Pb-DO3A-PEG7-Tz

[212Pb]Pb-DO3A-PEG7-Tz

Also written as [Pb-212]Pb-DO3A-PEG7-Tz

Radionuclide: Pb-212 t½ 638.4 min
Modality: Therapy
Production route: —
Stage: preclinical study
Syntheses indexed: 2

Hepatobiliary and pancreatic cancer Other radioligand therapy

What it is

Compound class: DOTA-type chelator (DO3A) tetrazine pretargeting probe
Target / mechanism: Pretargeting via tetrazine-trans-cyclooctene (TCO) click reaction with TCO-modified antibody PMID 37945380
Clinical application: Targeted alpha-particle therapy (TAT) for pancreatic ductal adenocarcinoma using pretargeted 212Pb PMID 37945380
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	—	—	DO3A-PEG7-Tz	37945380 2024 J Nucl Med
—	—	—	—	—	DOTA-Tz	29129050 2017 Bioconjug Chem

Need this precursor?We can point you to suppliers for [212Pb]Pb-DO3A-PEG7-Tz, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37945380. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37945380: '[212Pb]Pb-DO3A-PEG7-Tz'. Stage set/updated at stage 23 from PMID 37945380: 'This foundational study demonstrated the feasibility and safety of pretargeted TAT with 212Pb in PDAC while considering dose limitations and potential adverse effects.'.